Literature DB >> 27867642

More options, more considerations: how new treatment options influence clinical decision making.

In Hae Park1.   

Abstract

Year:  2016        PMID: 27867642      PMCID: PMC5107477          DOI: 10.21037/jtd.2016.10.63

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN: 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  5 in total

Review 1.  Second consensus on medical treatment of metastatic breast cancer.

Authors:  S Beslija; J Bonneterre; H Burstein; V Cocquyt; M Gnant; P Goodwin; V Heinemann; J Jassem; W J Köstler; M Krainer; S Menard; T Petit; L Petruzelka; K Possinger; P Schmid; E Stadtmauer; M Stockler; S Van Belle; C Vogel; N Wilcken; C Wiltschke; C C Zielinski; H Zwierzina
Journal:  Ann Oncol       Date:  2006-07-10       Impact factor: 32.976

Review 2.  Capecitabine monotherapy: review of studies in first-line HER-2-negative metastatic breast cancer.

Authors:  Joyce A O'Shaughnessy; Manfred Kaufmann; Friederike Siedentopf; Philippe Dalivoust; Marc Debled; Nicholas J Robert; Nadia Harbeck
Journal:  Oncologist       Date:  2012-03-14

3.  Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer.

Authors:  Martin R Stockler; Vernon J Harvey; Prudence A Francis; Michael J Byrne; Stephen P Ackland; Bernie Fitzharris; Guy Van Hazel; Nicholas R C Wilcken; Peter S Grimison; Anna K Nowak; M Corona Gainford; Akiko Fong; Lisa Paksec; Tatiana Sourjina; Diana Zannino; Val Gebski; R John Simes; John F Forbes; Alan S Coates
Journal:  J Clin Oncol       Date:  2011-10-24       Impact factor: 44.544

4.  Taxanes versus S-1 as the first-line chemotherapy for metastatic breast cancer (SELECT BC): an open-label, non-inferiority, randomised phase 3 trial.

Authors:  Tsutomu Takashima; Hirofumi Mukai; Fumikata Hara; Nobuaki Matsubara; Tsuyoshi Saito; Toshimi Takano; Youngjin Park; Tatsuya Toyama; Yasuo Hozumi; Junji Tsurutani; Shigeru Imoto; Takanori Watanabe; Yoshiaki Sagara; Reiki Nishimura; Kojiro Shimozuma; Yasuo Ohashi
Journal:  Lancet Oncol       Date:  2015-11-27       Impact factor: 41.316

5.  A randomized phase III study evaluating pegylated liposomal doxorubicin versus capecitabine as first-line therapy for metastatic breast cancer: results of the PELICAN study.

Authors:  Nadia Harbeck; Steffen Saupe; Elke Jäger; Marcus Schmidt; Rolf Kreienberg; Lothar Müller; Burkhard Joerg Otremba; Dirk Waldenmaier; Julia Dorn; Mathias Warm; Michael Scholz; Michael Untch; Maike de Wit; Jana Barinoff; Hans-Joachim Lück; Philipp Harter; Doris Augustin; Paul Harnett; Matthias W Beckmann; Salah-Eddin Al-Batran
Journal:  Breast Cancer Res Treat       Date:  2016-10-31       Impact factor: 4.872

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.